HomeInsightsStock Comparison

Gujarat Themis Biosyn Ltd vs Kopran Ltd Stock Comparison

Gujarat Themis Biosyn Ltd vs Kopran Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 371.85 as of 01 Aug 15:30.
  • The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Kopran Ltd changed from 5.2 on March 2020 to 24.5 on March 2024 . This represents a CAGR of 36.34% over 5 years.
  • The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Kopran Ltd changed from ₹ 109.65 crore on March 2020 to ₹ 1245 crore on March 2024 . This represents a CAGR of 62.59% over 5 years.
  • The revenue of Gujarat Themis Biosyn Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Kopran Ltd for the Jun '25 is ₹ 137.77 crore as compare to the Mar '25 revenue of ₹ 175.62 crore. This represent the decline of -21.55%.
  • The ebitda of Gujarat Themis Biosyn Ltd for the Jun '25 is ₹ 0 crore as compare to the Mar '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Kopran Ltd for the Jun '25 is ₹ 16.69 crore as compare to the Mar '25 ebitda of ₹ 20.35 crore. This represent the decline of -17.99%.
  • The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of 0.0% The net profit of Kopran Ltd changed from ₹ 2.77 crore to ₹ 7.45 crore over 9 quarters. This represents a CAGR of 55.23% .
  • The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 10.12 % on March 2020 to 12.27 % on March 2024 . This represents a CAGR of 3.93% over 5 yearsThe Dividend Payout of Kopran Ltd changed from 55.28 % on March 2021 to 41.75 % on March 2024 . This represents a CAGR of -6.78% over 4 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Gujarat Themis Biosyn Ltd

  • Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
  • It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is being actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Kopran Ltd

  • Kopran Ltd., incorporated on April 26, 1958, was promoted by the Somani group and is controlled by Parijat Enterprises.
  • The company came out with a public issue at a premium, in Nov.'92, to finance its backward integration project to produce drug intermediates for semi-synthetic drugs, and also to expand its antibiotic facility. Kopran manufactures pharmaceutical finished dosage forms and bulk drugs and distributes electronic equipment.
  • It manufactures semi-synthetic penicillin and is among the world's highest producers in amoxycillin.
  • Kopran also makes penicillin-G acylase, an enzyme made through fermentation.
  • It has technical collaborations with Gesellschaft Fur Biotechnologische, Germany; Yuhan Corporation, South Korea; Ciba Corning Diagnostic, US; and Adac Laboratories, US. Kopran's bulk drug plant has been approved by the US FDA and the UK regulatory authorities.

Gujarat Themis Biosyn Ltd News Hub

News

Gujarat Themis Biosyn to announce Quarterly Result

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 1 Au...

Read more

26 Jul 2025 10:34

News

Board of Gujarat Themis Biosyn recommends final dividend

Gujarat Themis Biosyn announced that the Board of Directors of the Company at its meeting ...

Read more

21 May 2025 11:36

News

Gujarat Themis Biosyn to announce Quarterly Result

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 20 M...

Read more

16 May 2025 15:57

News

Gujarat Themis Biosyn to convene board meeting

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 14 F...

Read more

11 Feb 2025 10:53

News

Board approved merger of Gujarat Themis Biosyn with Themis Medicare

The Board of Directors of Gujarat Themis Biosyn (GTBL) and Themis Medicare (TML) have appr...

Read more

19 Nov 2024 09:10

News

Gujarat Themis Biosyn schedules board meeting

Gujarat Themis Biosyn will hold a meeting of the Board of Directors of the Company on 25 O...

Read more

19 Oct 2024 09:25

Kopran Ltd News Hub

News

Kopran to hold AGM

Kopran announced that the 66th Annual General Meeting(AGM) of the company will be held on ...

Read more

31 Jul 2025 09:15

News

Kopran to table results

Kopran will hold a meeting of the Board of Directors of the Company on 29 July 2025. Power...

Read more

19 Jul 2025 10:03

News

Board of Kopran recommends final dividend

Kopran announced that the Board of Directors of the Company at its meeting held on 15 May ...

Read more

15 May 2025 16:01

News

Kopran to hold board meeting

Kopran will hold a meeting of the Board of Directors of the Company on 15 May 2025. Powere...

Read more

07 May 2025 14:37

News

Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly

The United States Food and Drug Administration (USFDA) recently carried out a surveillance...

Read more

28 Apr 2025 15:03

News

Kopran to declare Quarterly Results

Kopran will hold a meeting of the Board of Directors of the Company on 11 February 2025. P...

Read more

05 Feb 2025 12:53

SWOT Analysis Of Gujarat Themis Biosyn Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Kopran Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Gujarat Themis Biosyn Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Kopran Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Kopran Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Kopran Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,051 Cr while Market cap of Kopran Ltd is 767 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Kopran Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Kopran Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Kopran Ltd?

As of August 2, 2025, the Gujarat Themis Biosyn Ltd stock price is INR ₹371.85. On the other hand, Kopran Ltd stock price is INR ₹158.95.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Kopran Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Kopran Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions